Apixaban API Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Apixaban API Market is segmented By Product ( 99% Purity, >99% Purity), By Application (2.5mg Tablet, 5mg Tablet), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Apixaban API Market Size

The global apixaban API market size was valued US$ YY billion in 2022 and is estimated to reach US$ YY billion by 2031, growing at a high CAGR during the forecast period (2024-2031). 

Apixaban is a white to pale yellow powder, which is soluble in water, act as an anticoagulant drug used to treat thromboembolic diseases sold under the trade name Eliquis. It acts by inhibiting coagulation which prevents the development of blood clots.

Apixaban API Market Summary

To Know More Insights - Download Sample

Source: DataM Intelligence Analysis (2020)

Apixaban API Market Dynamics

The apixaban API market growth is driven by the increasing prevalence of venous thromboembolism events, rising government and private organizations investments in R&D and FDA approval of apixaban drugs for clinical purpose.

Increasing prevalence of venous thromboembolism events, is expected to drive the growth in the forecast period

Venous thromboembolism (VTE) refers to a blood clot in a vein, which is considered as third leading vascular diagnosis after a heart attack and stroke. For instance, according to the American Heart Association, VTE affects around 300,000 to 600,000 Americans annually. In the US, Pulmonary embolism (PE) among hospital patients is the most common & preventable cause of death. These VTE and PE are the two major public health issues. The apixaban enables to decrease the risk of stroke and embolism in patients with non-valvular atrial fibrillation. The drug is used for prophylaxis to prevent deep vein thrombosis, which may lead to pulmonary embolism, among patient’s undergone knee or hip replacement surgery.

Rising government and private organizations investments in R&D, is expected to drive the growth in the forecast period

The apixaban, edoxaban, and dabigatran drugs are direct oral anticoagulants, which received FDA approval for AF (Atrial Fibrillation), which have simplified medical management in these patients. The ARISTOTLE trial showed that the apixaban is superior to warfarin to reduce stroke and systemic embolism in patients with AF. For instance, Pfizer and Bristol-Myers Squibb collaborated to develop and commercialize the apixaban, and the alliance strengthens both companies to expand potential in cardiovascular drug development and commercialization. In addition, Pfizer, with BMS, continues to produce robust evidence on Eliquis (apixaban) performance through ACROPOLIS, which has analyzed more than 1 million lives in 11 countries. Moreover, in 2018, analyses from ARISTOPHANES, the study of oral anticoagulant use NVAF patients, were presented at three major medical congresses and published in the medical journal, Stroke. The outcome from ARISTOPHANES complements clinical trial data by offering effectiveness and safety outcomes.

Cost-effective alternative to warfarin, is expected to drive the growth in the forecast period

Apixaban drug is the third non-vitamin K antagonist oral anticoagulants, which are used for clinical practice. The regular dose of apixaban is effective in decreasing thromboembolic events as compared with warfarin. Moreover, the risk of major bleeding is considerably low for apixaban compared with dabigatran, warfarin, and rivaroxaban. For instance, in December 2019, the U.S. Food and Drug Administration approved the first generics of Eliquis (apixaban) tablets, and FDA’s generic drug program enables access to cost-effective, high-quality drugs.

Complications associated with apixaban is likely to hamper the market growth

Apixaban can cause a very serious blood clot around the spinal cord if a patient undergoes a spinal tap or receive spinal anesthesia (epidural), especially having a genetic spinal defect, if the patient has a spinal catheter in place or have a history of spinal surgery or repeated spinal taps, or also using other drugs that can affect blood clotting. This type of blood clot can lead to long-term or permanent paralysis.

Apixaban API Market Industry Analysis

PEST Analysis:

Source: DataM Intelligence Analysis (2020)

Supply Chain Analysis

Source: DataM Intelligence Analysis (2020)

COVID-19 Impact Analysis

COVID-19 outbreak created considerable scope for the global apixaban API market. The respiratory involvement, the patient of the COVID-19, often develops a pro-coagulative state caused by the virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. Various medications are being used for the treatment of the COVID-19 patients. For instance, drugs like sarilumab (KEVZARA) and tocilizumab (ACTEMRA) can increase cytochrome P450 enzyme activity and so they should not be used together with the apixaban (Eliquis) or rivaroxaban (Xarelto) and may also increase the doses of warfarin required. The thrombotic risk is associated with disease severity and worsens patients’ prognosis; however, the management strategies need to be assessed.

Apixaban API Market Segment Analysis

The 99 % purity segment is expected to hold largest share in this market segment

The 99% Purity segment is dominating due to the high sales and large volume and presence many manufacturers.

The 2.5 mg segment is expected to hold largest share in this market segment

The 2.5 mg apixaban segment dominating the market growth. For instance, according to the Australian Government Department of Health, Apixaban 2.5 mg tablets are currently PBS Pharmaceutical benefits scheme listed as an Authority Required benefit for prevention of venous thromboembolism in patients undergoing total hip or total knee replacement.

Source: DataM Intelligence Analysis (2020)

Global Apixaban API Market Geographical Share

North America region holds the largest market share of global apixaban API market

North America region is dominating the silage inoculants & enzymes market, followed by APAC and Europe. The economy of North America is mainly influenced by the economic dynamics of countries such as the US and Canada. For instance, according to the American Heart Association, VTE affects around 300,000 to 600,000 Americans annually. In the US, Pulmonary embolism (PE) among hospital patients is the most common & preventable cause of death. For instance, in August 2017, Bristol-Myers Squibb Company and Pfizer Inc. announced that 15 abstracts have been accepted for presentation at the European Society of Cardiology Congress, the investigational data from the EMANATE [Eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with non-valvular atrial fibrillation (NVAF)] clinical trial. The company collaborated with Pfizer Inc. to reduce the risk of stroke caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress. The EMANATE is a Phase 4 clinical trial exploring Eliquis (apixaban) against standard oral anticoagulation with a vitamin K antagonist in patients with NVAF.

Source: DataM Intelligence Analysis (2020)

Apixaban API Market Companies and Competitive Landscape

The global apixaban API market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include Neuraxpharm / INKE, Amtec Health Care Pvt. Ltd, Basic Pharma Life Science Pvt Ltd, Tianyu Pharm, Element Chemilink Pvt Ltd, Teva, Mehta API Pvt Ltd, Jinan Jianfeng Chemical Co., Ltd, Hisun, CTX Life Sciences. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Apixaban API Market Key Companies to Watch

Neuraxpharm / INKE

Overview: Inke, a wholly-owned subsidiary of Neuraxpharm, has been manufacturing the highest quality API since 1980, headquartered in Barcelona (Spain). Development and manufacturing of API with complex synthesis process. More than 20 years of experience in micronization. It has continuously undergone international expansion since 1998 and a strong international presence with the sale of APIs to more than 30 countries. Inke delivers APIs worldwide, including Europe, the US, Japan, Korea and China.

Product Portfolio: The company mainly for use in respiratory and CNS therapies.

Why Purchase the Report?

• Visualize the composition of the apixaban API market segmentation by product, application and region highlighting the key commercial assets and players.
• Identify commercial opportunities in apixaban API market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of apixaban API market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global apixaban API market report would provide an access to an approx. 53 market data table, 40 figures and 200 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers